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Background of the European Liver Transplant Registry
Since 1968 the European Liver Transplant Registry (ELTR) collects
prospectively the data of liver transplantation (LT) in 145 centers
all over Europe. It represents more than 95% of the overall
European data compared to the published ofﬁcial ﬁgures [1]. This
collection is made prospectively through a standardized question-
naire. The ﬁrst part of the questionnaire includes items regarding
date and indication for LT, donor and recipient data, surgical tech-
nique of LT, and the immediate postoperative immunosuppression
therapy. The second part concerns graft and patient outcome, and
immunosuppressive regimen follow-up. Participation in the ELTR
is voluntary and a standard computerized database is provided to
contributing centers with detailed instructions for the collection
of accurate and uniform information [2].Journal of Hepatology 20
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[3–12], ELTR has allowed the development of riskmodels for liver-
transplantation mortality according to the characteristics of the
donor and recipient, and of the transplant procedure [13,14].
Quality of the data is assessed routinely. A regular auditing pro-
cess is conducted each year to ensure the reliability of the scientiﬁc
analysis of the data, a control of the good adequacy between ELTR
questionnaire and patient charts is performed by randomly con-
ducted audit visits. Results of these audit visits have indicated that
ELTR data were reliable and the scientiﬁc results of ELTR can be
considered credible and representative of LT in Europe [15–18].
In addition, a control quality program has been developed inter-
nally. The data are subjected to checks for completeness, consis-
tency, and range. Comprehensive logical intra- and inter-updates
are performed. Moreover, the ELTR has established agreements
with the European Organ Sharing Organizations (OSO): United
Kingdom Transplant Service Support Authority (UKTransplant),
Spanish Organizaciòn Nacional de Transplantes (ONT), Scandina-
vian Scanditransplant (SKT), Dutch Transplant Foundation (NTS),
Eurotransplant (ET), French Agence de la Biomédecine (ABM) to
exchange data collected from European Centers and to cross check
common data between OSO and ELTR.Patients and methods
We have ﬁrst considered all data since 1968 to show the evolu-
tion of results of LT in Europe since its initial development. The
rest of the analysis has been undertaken during two different
periods: (a) from January 1988 to December 2009 (89,865 LT –
80,347 patients), where the date from January 1988 was chosen12 vol. 57 j 675–688
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Fig. 1. Number of LTs performed in each country, overall and living related liver transplantation (LRLT) (May 1968–December 2009).
Frontiers in Liver Transplantationas corresponding to the diffusion of cyclosporine-based immuno-
suppression and to the standardization of the surgical procedure,
(b) the last 10-year period data from January 2000 to December
2009 (54,088 LT – 48,218 patients) to give a more recent evalua-
tion of LT results in Europe.
Data were analyzed as a whole without distinction of pediat-
ric transplants that represent 10% of LTs in Europe.
Data are analyzed with Statistical Analysis System (SAS). The
dynamics of data control are continued during the statistical ana-
lyzes. Calculation of survival rates are determined by the actuar-
ial method.Results
From May 1968 to December 2009, the ELTR collected data con-
cerning 93,634 liver transplantations (LTs) in 83,816 patients
from 145 centers of 26 countries (Fig. 1). These data give a com-
prehensive overview of the status and evolution of LT in Europe.
Both the number of transplant centers and the annual number of
LTs performed in Europe have gradually increased since the cre-
ation of ELTR (Fig. 2). However, after an exponential increase676 Journal of Hepatology 201from the eighties, a plateau has become to be reached in recent
years with about 5800 LTs performed all over Europe.
Main indications for LT in Europe
Main indications for LT in Europe with the corresponding graft
and patient survival rates at 1, 5 and 10 years are listed in Table 1.
Cirrhosis is the most frequent indication (52%), mainly related to
either viral infection (21% with 13% of hepatitis C virus infection
(HCV) and 7% of hepatitis B virus infection (HBV)), or alcohol
abuse (19%). Combined viral and alcoholic (ALD) cirrhosis repre-
sents 3% of cases, with 2% of HCV–ALD. Cirrhosis is followed by
three major indications: primary liver tumors (14% with 12.1%
of hepatocellular carcinoma), cholestatic disease (11%), and acute
hepatic failure (8%, 2% of which are virus-related). Cholestatic
disease includes primary biliary cirrhosis (6%) and extra-hepatic
biliary atresia (4%). Primary sclerosing cholangitis represents 4%
of cases. Biliary atresia is the most frequent indication (57%) in
the pediatric population, followed by metabolic disease (19%).
Metabolic disease represents 6% of indications with familial
amyloïdotic polyneuropathy as the major indication (2%),
followed by three indications of equal frequency (1%): Wilson2 vol. 57 j 675–688
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Fig. 2. Evolution of 93,634 LTs performed in Europe since May 1968. Arrows indicate the year the ﬁrst LT was performed in indicated countries. ⁄This decrease is owed to
the fact that some centers did not yet send their updating further to the recent changes of the questionnaire.
JOURNAL OF HEPATOLOGYdisease, alpha-1-antitrypsin deﬁciency and hemochromatosis.
Secondary tumors (mainly carcinoid), Budd Chiari and benign
liver tumors (mainly polycystic disease) represent only 1% of indi-
cations in Europe.
The percentage of main indications for LT has signiﬁcantly
changed with time. While cancers represented 50% of indications
before 1980, they dramatically decreased during the nineties
(10%) before resuming a linear increase since 2000, to currently
represent more than 20%. Conversely, acute hepatic failure that
led anecdotally to LT before 1986 has since become a recognized
indication for LT. (Fig. 3).
In the 10 recent years, two groups of indication have shown
an increase: primary liver tumors (16%), mainly related to HCC,
and cirrhosis (53%), mainly alcoholic (20%). Drug-related fulmin-
ant hepatitis is henceforth the leading disease in the group of
acute hepatic failures. In the same way, primary sclerosing cho-
langitis is the main indication in the group of cholestatic diseases.
Patient and graft survival of this 10-recent-year population are
summarized in Table 1.
Mortality of LT
One, 3 and 6-month patient’s survivals were 90%, 85% and 82%
before 2000. Survival rates dramatically increased to reach 94%,
91% and 88%, respectively. The critical period for post-LT outcome
is the ﬁrst 6 months: 46% of deaths and 65% of re-LT occursJournal of Hepatology 201within 6 months after LT (Fig. 4). In 49% of cases, re-LT is indi-
cated in the month after primary LT, and one quarter of deaths
occurs within the ﬁrst month after LT.
Data represented in Tables 2 and 3 correspond to main cause
of death or graft failure. Main causes of death in the 18,186
patients (about 23%) who died after primary LT or re-LT were,
by decreasing order: (1) general causes as multiple organ failure
and cerebrovascular, cardiovascular, pulmonary, and renal com-
plications (29%); (2) recurrence of primary disease (20%), mostly
cancer (11%); (3) sepsis (18%) mostly bacterial (9%); (4) technical
complications (5%), mostly hemorrhage and vascular (3%); and
(5) rejection (4%) mostly chronic (3%) (Table 2). Intra-operative
deaths and primary non-function represented 3% of all deaths.
When we consider only the patients who survive beyond
6 months (Fig. 5), there are less technical complications, infection
and general complications (cerebrovascular, cardiovascular, pul-
monary, and renal), but more tumoral and non-tumoral recur-
rences, de novo tumor and rejection.
The data of the last 10 years show a decrease in overall mor-
tality (16%) with the same distribution of the causes of death
observed in the population from 1988.
Overall patient survival
When all indications are considered during the entire study per-
iod, patient survival rates are 82% at 1 year, 71% at 5 years, 61% at2 vol. 57 j 675–688 677
Table 1. Primary indications for LT in Europe and the corresponding survival.
From 1988 to 2009 Last 10 years [1999-2009]
Percentage Survival rate (%)
yr
Percentage Survival rate (%)
yr
No. 
patients
of the
disease
(%)
of the 
total
(%)
1 5 10 15 20 No. 
patients
of the 
disease
(%)
of the 
total
(%)
1 5 
Indication for LT Graft
(%)
Patient Graft
(%)
Patient Graft
(%)
Patient Graft
(%)
Patient Graft
(%)
Patient Graft
(%)
Patient Graft
(%)
Patient
Acute hepatic failure 6507 8 64 70 56 64 51 58 44 53 38 47 3449 7 70 76 62 69
Virus 1251 19 2 67 73 57 65 50 58 41 52 35 46 645 19 1 75 80 65 72
Drug 1187 18 1 66 71 57 63 49 55 42 48 39 45 728 21 2 70 75 61 66
Toxic 242 4 0.3 67 71 63 68 58 64 54 61 40 61 164 5 0.3 69 73 64 69
Postoperative/traumatic 178 3 0.2 40 50 35 45 33 44 26 44 - - 120 3 0.2 47 57 43 55
Unknown/others 3649 56 5 63 69 56 64 52 59 46 55 39 49 1792 52 4 69 76 63 70
Cholestatic disease 9114 11 79 87 70 78 62 70 45 59 30 44 4675 10 83 89 74 81
Primary biliary cirrhosis 4515 50 6 81 86 75 80 66 71 53 59 43 48 1929 41 4 85 90 78 83
Primary sclerosing cholangitis 3582 39 4 80 87 69 78 57 70 45 59 30 44 2170 46 5 83 90 72 82
Secondary biliary cirrhosis 550 6 1 70 75 60 65 50 57 47 54 47 54 307 7 1 71 76 61 65
Others 467 5 1 77 83 69 77 61 71 51 60 30 60 269 6 1 74 81 62 73
Congenital biliary disease 4152 5 79 86 74 83 70 80 65 77 59 73 2167 4 84 90 79 87
Extrahepatic biliary atresia 3346 81 4 79 87 74 83 71 81 68 79 62 75 1662 77 3 85 91 80 88
Alagille syndrom 228 5 0.3 79 84 73 81 69 77 54 73 54 73 147 7 0.3 83 88 79 85
193 5 0.2 81 87 76 81 68 75 63 70 - 60 98 5 0.2 88 92 84 91
Caroli disease 196 5 0.2 78 87 69 81 63 78 40 60 - - 138 6 0.3 77 86 67 83
Choledocal cyst 37 1 0.05 86 86 75 86 52 73 20 49 - - 17 1 0.04 74 74 46 74
Others 152 4 0.2 82 86 76 81 70 80 61 72 - - 105 5 0.2 85 88 80 84
Cirrhosis 41,593 52 79 83 67 72 56 61 46 51 37 42 25,424 53 81 85 69 73
Virus related cirrhosis 18,348 44 23 78 82 64 69 54 59 46 51 38 43 11,030 43 23 80 88 65 74
     Virus B 4187 10 5 79 83 69 74 63 68 56 61 46 49 2400 9 5 84 87 75 79
     Virus C 10,753 26 13 76 80 60 65 48 53 38 43 29 33 6590 26 14 77 81 59 64
     Virus BD 1382 3 2 87 92 82 87 77 84 71 79 66 76 835 3 2 89 93 83 88
     Virus BC 683 2 1 76 81 64 71 54 60 49 54 43 54 407 2 1 77 82 67 74
     Virus BCD 165 0 0.2 89 91 80 82 63 66 50 53 37 40 106 0.4 0.2 90 91 82 83
     Other viruses 1178 3 1.5 81 84 64 69 53 59 45 50 36 40 692 3 1.4 83 87 63 69
Alcoholic cirrhosis 15,019 36 19 81 86 69 73 55 59 44 48 33 36 9555 38 20 83 86 71 75
Combined viral and alcoholic 2244 5 3 82 87 67 72 51 56 38 41 33 35 1531 6 3 84 88 70 74
     Viral C and alcoholic 1790 4 2 81 85 65 69 50 54 37 40 30 31 1228 5 3 84 86 69 73
     Viral B and alcoholic 454 1 1 85 89 74 79 59 62 41 45 41 45 303 1 1 88 92 76 80
Cryptogenic (unknown) 3443 8 4 76 81 66 72 57 63 48 54 34 42 1892 7 4 79 83 69 74
Autoimmune cirrhosis 1892 5 2 80 85 69 76 59 67 48 57 46 55 1069 4 2 84 88 72 80
Drug-related 68 0.2 0 74 77 68 72 62 66 - - - - 31 0.1 0.06 75 77 70 77
Others 579 1 1 68 73 58 63 49 54 41 46 26 20 316 1 0.7 83 87 63 65
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From 1988 to 2009 Last 10 years [1999-2009]
Percentage Survival rate (%)
yr
Percentage Survival rate (%)
yr
No. 
patients
of the
disease
(%)
of the 
total
(%)l
1 5 10 15 20 No. 
patients
of the 
disease
(%)
of the 
total
(%)
1 5 
Indication for LT Graft
(%)
Patient Graft
(%)
Patient Graft
(%)
Patient Graft
(%)
Patient Graft
(%)
Patient Graft
(%)
Patient Graft
(%)
Patient
Primary liver tumors 10,991 14 72 76 49 52 40 40 34 37 24 27 7640 16 81 83 61 64
Hepatocellular carcinoma and 
cirrhosis
9122 83 11 80 83 58 62 46 49 37 40 25 29 6874 90 14 82 86 62 66
Hepatocellular carcinoma and 
non-cirrhotic liver
638 6 1 67 71 40 43 29 31 24 26 20 23 215 3 0.4 78 84 57 61
Hepatic cholangiocellular 
carcinoma
332 3 0.4 62 66 28 31 19 21 14 17 - - 142 2 0.3 73 79 33 37
Biliary tract carcinoma 
(Klatskin)
252 2 0.3 64 66 30 32 22 24 14 16 12 13 79 1 0.2 65 68 32 37
Hepatoblastoma 180 2 0.2 81 84 69 74 61 69 58 66 - - 127 2 0.3 82 86 70 76
Epithelioid 
hemangioendothelioma
159 1 0.2 81 88 71 77 67 72 58 67 58 67 96 1 0.2 81 90 76 84
Hepatocellular carcinoma- 50 0.5 0.1 65 70 32 36 27 33 27 33 - - 18 0.2 0.04 65 71 30 38
Angiosarcoma 21 0.2 0.03 27 33 7 13 - - - - - - 5 0.1 0.01 56 56 - -
Other liver malignancies 237 2 0.3 67 71 41 43 36 38 29 31 - - 84 1 0.2 81 87 49 53
Secondary liver tumors 516 1 74 79 43 50 29 32 24 25 15 15 361 1 77 83 50 55
Carcinoid 196 38 0.2 81 86 55 58 33 34 24 24 16 16 109 30 0.2 85 90 63 66
Other neuroendocrine 160 31 0.2 69 74 44 49 27 30 26 26 - - 108 30 0.2 70 76 46 59
Colorectal 47 9 0.1 70 79 31 33 14 14 - - - - 25 7 0.1 78 86 33 37
GI non-colorectal 15 3 0.02 72 72 36 36 29 29 29 29 - - 5 1 0.01 80 85 - -
Non-gastrointestinal 18 3 0.02 64 64 24 24 - - - - - - 6 2 0.01 75 80 - -
Others 80 16 0.1 61 65 28 32 18 22 15 19 - - 108 30 0.2 - - - -
Metabolic diseases 4855 6 80 86 72 78 63 70 57 65 48 59 2866 6 82 87 72 79
Familial amyloïdotic 
polyneuropathy
1280 26 2 81 87 69 76 56 62 43 50 - - 873 30 2 82 88 68 76
Wilson disease 812 17 1 81 88 76 84 68 79 62 75 56 70 514 18 1 84 90 78 85
542 11 1 84 89 77 83 68 75 63 69 37 63 293 10 1 88 91 83 87
Hemochromatosis 468 10 1 73 76 63 66 49 53 38 39 - - 269 9 1 75 78 62 66
225 5 0.3 79 84 65 71 53 59 53 56 - - 155 5 0.3 80 86 62 67
Byler disease 212 4 0.3 83 93 80 92 77 87 72 83 72 83 101 4 0.2 85 94 79 92
Primary hyperoxaluria 230 5 0.3 79 85 71 78 65 71 60 67 60 67 148 5 0.3 77 85 70 78
Tyrosinemia 98 2 0.1 84 91 73 85 72 83 69 83 69 83 35 1 0.1 87 90 67 84
Glycogen storage disease 95 2 0.1 83 90 79 86 79 86 68 73 59 62 66 2 0.1 84 91 76 82
Non-alcoholic steatohepatitis 86 2 0.1 85 87 83 84 62 63 - - - - 84 3 0.2 85 86 83 84
Crigler-Najjar 59 1 0.1 88 97 79 92 79 92 79 92 - - 31 1 0.1 86 100 76 95
Homozygous 
hypercholesterolemia
21 0.4 0.0 83 83 74 74 50 74 50 74 - - 15 1 0.03 83 83 64 64
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Table 1 (continued)
From 1988 to 2009 Last 10 years [1999-2009]
Percentage Survival rate (%)
yr
Percentage Survival rate (%)
yr
No. 
patients
of the
disease
(%)
of the 
total
(%)l
1 5 10 15 20 No. 
patients
of the 
disease
(%)
of the 
total
(%)
1 5 
Indication for LT Graft
(%)
Patient Graft
(%)
Patient Graft
(%)
Patient Graft
(%)
Patient Graft
(%)
Patient Graft
(%)
Patient Graft
(%)
Patient
Protoporphyria 19 0.4 0.0 78 84 72 72 66 66 57 57 57 57 7 0.2 0.01 68 68 48 48
Others 708 15 1 79 84 69 75 62 69 60 67 58 62 275 10 1 - - - -
Budd-Chiari 712 1 72 78 64 71 55 64 49 59 40 49 400 1 76 81 66 73
Benign liver tumors or 
polycystic disease
1015 1 83 86 77 82 71 75 64 68 61 65 733 2 85 89 79 85
Polycystic disease 732 72 1 86 89 80 85 73 77 66 69 66 69 548 75 1 88 91 81 87
Hemangioma 99 10 0.1 80 85 78 84 73 80 66 72 - - 60 8 0.1 79 84 75 82
Adenomatosis 38 4 0.05 83 83 74 74 74 74 74 74 - - 27 4 0.06 85 85 85 85
Nodular regenerative 
hyperplasia
33 3 0.04 81 81 63 63 63 63 52 52 - - 19 3 0.04 88 88 68 68
Hepatic adenoma 27 3 0.03 60 71 50 61 33 61 33 61 - - 19 3 0.04 71 77 55 61
Focal nodular hyperplasia 16 2 0.02 74 93 66 93 45 51 - - - - 12 2 0.02 74 91 74 91
Others 70 7 0.1 71 79 63 73 57 57 57 62 - - 48 7 0.1 68 73 63 70
Parasitic disease 68 0.1 75 77 67 68 56 57 52 53 26 27 31 0.1 81 81 55 55
Alveolar echinococcosis 47 69 0.1 77 79 67 69 55 57 49 52 30 31 23 74 0.05 89 89 62 62
Cystic hydatidosis 7 10 0.01 57 57 43 43 43 43 43 43 - - 4 13 0.01 - - - -
Schistosomiasis (Belharzia) 4 6 0.005 75 75 - - - - - - - - 2 6 0.004 - - - -
Others 10 15 0.01 80 80 80 80 - - - - - - 2 6 0.004 - - - -
Other liver diseases 824 1 71 74 61 66 52 57 47 53 44 51 472 1 74 79 66 71
Total 80,347 100 75 82 63 71 53 61 44 51 36 43 48,218 100 79 85 66 73
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JOURNAL OF HEPATOLOGY10 years, 51% at 15 years and 43% at 20 years. When we consider
only the patients who survive beyond 6 months, patient survival
rates are dramatically higher (96% at 1 year, 83% at 5 years, 71% at
10 years, 61% at 15 years and 52% at 20 years). After an improve-
ment between 1988 and 2000, the survival of these patients
appears to be relatively steady since 2000 (Fig. 6).
Survival has improved regularly year after year, reaching 85%
at 1 year after 2004 compared with 76% in 1990–1994 and only
33% before 1985 (Fig. 7). The improvement concerns all the indi-
cations but particularly LT for cancers (Fig. 8).Journal of Hepatology 201When we consider the last 10-year period, survival of patients
transplanted in the recent 10 years has improved to reach 85% at
1 year and 73% at 5 years.
Survival of pediatric versus adult liver transplant recipients
Ten percent of LTs have been performed in pediatric patients
(<15 years), with 3.4% of children younger than 2 years. Five-year
survival in children is signiﬁcantly better than in adults (79% vs.
70%, p <0.0001). In the pediatric population, 5-year survival rate
is identical for children under 2 years and for those aged 3 to
15 years (79%).
In the 10 last years, the rate of pediatric LT has decreased to
8% and the corresponding 5 year-survival is still better than in
adults (82% vs. 72%, p <0.0001).
Survival according to the indication for LT
The 5-year patient survival rate is signiﬁcantly better for cirrhosis
(72%) than for primary liver tumors (52%, p <0.001) and acute
hepatic failure (64%, p <0.001). In viral cirrhosis, HBV and HCV
co-infection have a better 5-year survival (82%) than mono-
infection with HCV (65%) or HBV (74%). The greater survival rates
obtained in metabolic diseases (78%), cholestatic disease (78%)
and congenital biliary disease (83%), occur partly because of the
high percentage of children in these groups. Details of survival
rates at 1, 5 and 10, 15 and 20 years according to the primary
indication are listed in Table 1.
Although 5-year survival in the last 10-year population was
improved in all indications, the most important gain in survival
was observed in LTs for primary liver tumors, which is presently
64%, liver metastases (55%) and acute hepatic failure (69%).2 vol. 57 j 675–688 681
Table 3. Recipient graft survival according to the type of LT in Europe.
Type of LT/graft From 1988 to 2009 Last 10 years [1999-2009]
No. 
grafts
Survival rate (%) No. 
grafts
Survival rate (%)
1 yr 5 yr 10 yr 15 yr 20 yr 1 yr 5 yr
Cadaveric  full size 68,728 78 65 55 46 36 40,268 81 68
Split liver 3919 73 65 56 50 50 2983 76 67
     Right 1728 76 66 52 43 - 1327 77 67
     Left 1738 72 65 59 51 - 1323 75 66
Living donor 3481 80 69 61 60 - 3099 80 68
     Right 2113 79 64 51 51 - 2051 79 65
     Left 1191 81 76 71 69 - 880 81 76
Reduced liver 1988 69 62 58 54 51 711 74 68
Domino (sequential) 665 81 59 41 - - 590 83 62
Table 2. Post-LT mortality after ﬁrst LT in Europe. Complications correspond to ﬁrst declared cause of death according to date of occurrence.
Cause of death Date of the mortality occurence Total Percentage of
1 d 1 wk 1 mo 6 mo 1 yr 3 yr 5 yr >5 yr the complication 
(%)
of the total 
(%)
Intra-operative death 508 0 0 0 0 0 0 0 508 100 3
Primary non-function 115 229 172 0 0 0 0 0 516 100 3
Technical 91 114 257 246 82 111 30 55 986 100 5
Haemorrhage 67 42 69 46 10 8 5 3 250 25 1
Vascular complications 21 59 157 96 35 35 9 20 432 44 2
Biliary complications 0 3 17 95 36 60 13 31 255 26 1
Hepatic infarction 3 10 14 9 1 8 3 1 49 5 0.3
Sepsis 22 142 801 1346 281 295 133 267 3287 100 18
Bacterial infection 13 81 390 633 139 154 74 181 1665 51 9
Fungal infection 1 9 125 181 24 24 11 10 385 12 2
Viral infection 0 4 23 121 21 19 4 11 203 6 1
Sepsis not designated 8 48 263 411 97 98 44 65 1034 31 6
Rejection 6 17 85 113 125 164 55 82 647 100 4
Chronic rejection 0 0 0 67 109 153 50 80 459 71 3
Acute rejection 6 16 82 43 13 10 5 1 176 27 1
Not designated 0 1 3 3 3 1 0 1 12 2 0.1
Recurrence of initial disease 0 1 10 362 616 1383 599 712 3683 249 20
Tumoral 0 0 1 214 382 850 338 267 2052 56 11
Non-tumoral 0 1 9 148 234 533 261 445 1631 44 9
Tumor de novo 1 0 5 76 149 450 381 731 1793 100 10
General causes 333 495 1055 1208 321 530 324 987 5253 100 29
Cardiovascular 181 155 232 230 77 152 115 369 1511 29 8
Cerebrovascular 55 144 185 198 64 113 43 164 966 18 5
Pulmonary 26 54 216 305 72 105 53 172 1003 19 6
Gastrointestinal 26 37 122 140 33 68 47 90 563 11 3
Renal 3 11 47 58 20 27 35 119 320 6 2
Mutiple organ failure 42 94 253 277 55 65 31 73 890 17 5
Other liver causes 7 32 68 54 25 40 27 62 315 100 2
Other or unknown causes 69 82 165 225 89 186 110 272 1198 100 7
Total 1152 1112 2618 3630 1688 3159 1659 3168 18,186 100 100
Frontiers in Liver Transplantation
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Donor characteristics
The majority of donors were male (59%). Seventy-six percent
were younger than 55 years, whereas 11% were older than
65 years. An increasing percentage of livers are coming from
donors older than 60 years (1% in 1989, 15% in 1999 and 29% in
2009), in relation to the increasing gap between a growing wait-
ing list and a relatively stable donor pool (Fig. 9). Graft survival
when organs were procured from donors younger than 55 years
was signiﬁcantly higher than that with organs from donors older
than 65 years (65% vs. 57% at 5 years, p <0.0001). With 71% atJournal of Hepatology 2011-year and 50% 5-year graft survival, there is no argument to dis-
card octogenarian grafts among aged subjects without associated
risk factors (Fig. 10).
When we consider the last 10-year period, 5-year graft sur-
vival was 69% with donors younger than 55 years and 59% with
donor older than 65 years. However, aged grafts are more fre-
quently transplanted to aged recipients (33% of grafts older than
60 years were used in recipients older than 70 years, and only
21% were used in recipients younger than 70 years, p <0.0001),
explaining at least in part, the difference in survival.2 vol. 57 j 675–688 683
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In addition to the already mentioned better 5-year survival of
pediatric vs. adult LT recipients, an inﬂuence of recipient age is
observed for adults. Survival rates are 74% for adults aged 16–
45 years, 70% for those aged 46–60 years, and 64% for those older684 Journal of Hepatology 201than 60 years. However, average age of transplanted recipients
has increased steadily during the last decade, and patients older
than 60 years, who represented less than 5% in the 1980s, repre-
sented approximately 25% of transplant recipients in 2009
(Fig. 11).
When we consider the last 10-year period, 5-year survival has
increased in all the subgroups of adult recipients to reach 77% for
adults of 16–45 years, 73% for 46–60 years and 66% over 60 years.
Blood group type matching
Ninety-two percent of LTs were isogroup, and 7.6% were compat-
ible. Only 0.6% were incompatible and restricted to urgent proce-
dures. In emergencies, isogroup and compatible LTs have similar
survival. In elective conditions, isogroup LTs have a better 5-year
survival than compatible LTs (66% vs. 60%, p <0.0001). Incompat-
ible LTs have a decreased 5-year graft survival rate as compared
to isogroup and compatible LTs (27% vs. 53%, p <0.0001). How-
ever, use of these incompatible grafts in emergency indications
allows around 50% survival rate in patients otherwise destined
to a fatal outcome.
Although 5 year-survival in the last 10-year population was
improved in all the groups of type matching, the most important
gain in survival was observed in incompatible matching (+41%).
However, only 0.3% of LTs were incompatible.
Survival according to surgical technique
More than 99% LTs were done orthotopically, and 87% of grafts
were full size. Alternative procedures to full size LTs have been
used increasingly in recent years (9% before 2000 vs. 16% after
2000). In the 2000s, alternative procedures were represented by
reduced livers (2%), split livers (6%) living donors (6%), and dom-
ino transplants (1%). 1, 5, 10, 15 and 20-year graft survivals of
each type of graft are summarized in Table 3. Survival at 5 years
was similar between split liver and cadaveric full size grafts
(65%), but lower than that of living donors (69%) and higher than
that of reduced and domino grafts (62% and 59%, respectively).
Auxiliary grafts represented 0.8% of overall LTs with a lower graft
survival as compared to non-auxiliary grafts in urgent indications
(5-year survival rates: 45% vs. 52%), and in elective indications
(60% vs. 66%, p <0.0001). Graft survival was better when cold
ischemia time was less than 12 h and University of Wisconsin
solution was used for preservation (p <0.001).
When we consider the last 10-year period, 5-year graft sur-
vival has increased in all types of graft to reach 68% for reduced
grafts, 67% for split and 62% for domino.
Living related LT in Europe
The ELTR has cumulated data concerning 3622 living related LTs
(LRLTs) performed in 78 centers from 20 countries from October
1991 to December 2009 (Fig. 1). The results of this technique will
be published elsewhere. In summary, adults represented 65% of
LRLTs. Since 2001 adult LRLTs largely exceeded pediatric LTs.
The donor surgical mortality rate was 0.18%. Overall 5-year graft
survival of LRLT was 69%, better for children than for adults (78%
vs. 63%, p <0.001). Whereas graft survival of LRLT was better than
cadaveric LT for children (78% vs. 72%, p <0.001), it was similar for
adults (64% vs. 63%). Overall, graft loss included more technical
complications (26% vs. 14%), more infection (23% vs. 18%), more
rejection (8% vs. 4%), more tumor recurrence (12% vs. 9%), but less2 vol. 57 j 675–688
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JOURNAL OF HEPATOLOGYgeneral complications (20% vs. 27%) and less non-tumor disease
recurrence (4% vs.12%) after LRLT than after cadaveric LT (all
p <0.05).
Re-LT
Main causes of re-LT
Re-LT was indicated in 5596 cases (7%) mainly for technical com-
plications (37%) (mostly vascular (27%) and biliary (10%)), for pri-
mary non-function (25%) and for rejection (19%), mainly chronic
(14%). Recurrence of primary disease (mostly non-tumoral) was
concerned in only 11% of cases (Table 4).
Survival
Five-year graft survival rates for the second and third LTs were
42% and 37%, respectively, signiﬁcantly lower than those for pri-
mary LT (65% – p <0.0001) (Fig. 12).
The data of the last 10 years show a decrease in the use of re-
LT (5%) with an increase of technical complications (41%) and aJournal of Hepatology 201decrease of rejection (10%). Moreover, 5-year graft survival was
increased in all the ranks of re-LT and the gap between primary
LT (68%) and 2nd LT (52%) has been reduced.Discussion
With more than 90,000-recorded LTs, the ELTR is a unique source
to evaluate the evolution and results of LT in Europe. It is repre-
sentative of LT in Europe (95% of LTs performed). Owing to a rou-
tine control of data including audit visits to randomly selected
centers, its scientiﬁc value has been recently emphasized [15–
18].
Almost 6000 LTs per year are currently performed in Europe, a
number similar to that of the United States (US). However, dona-
tion rates in Europe vary much more than in United Network for
Organ Sharing (UNOS) regions. Spain has by far the highest dona-
tion rate in Europe (34.2 per million inhabitants in 2008) fol-
lowed by most of the other European countries with a rate of
organ donation between 20 and 25 per million inhabitants, sim-
ilar to that of Region 8 in the US (Colorado, Kansas, Nebraska and
Wyoming) which has the highest donation rate (24 per million
inhabitants in 2008) [19]. To cope with a donor shortage that
presently represents the most important limiting factor of LT,
alternatives to cadaveric LT such as split, domino, or living related
LTs are increasingly used accounting for 15% of all procedures.
Although more technically demanding, these techniques give
results similar to that for cadaveric LT and allow a larger number
of patients to undergo LT. Nevertheless, they need high expertise
from the centers [13,14]. This expertise is also likely to minimize
the risk for donors in case of LRLT, although no relationship has
been clearly demonstrated between the centre’s expertise and
the diminution of the risk of donor mortality and morbidity.
In terms of indications, two main issues emerge from the
European experience: (1) as expected, cirrhosis continues to rep-
resent the main indication of LT with more than half of the2 vol. 57 j 675–688 685
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Table 4. Cause of re-LT after the ﬁrst LT in Europe. The complications correspond to the ﬁrst cause of failure declared according to time of occurrence.
Cause of retransplantation Date of  retransplantation occurrence Total Percentage of 
1 d 1 wk 1 mo 6 mo 1 yr 3 yr 5 yr >5 yr the complication
(%)
the total
(%)
Primary non-function 152 952 309 0 0 0 0 0 1413 100 25
Technical 39 381 584 474 169 245 88 111 2091 100 37
Vascular complications 37 362 525 320 76 95 35 47 1497 72 27
Biliary complications 1 5 34 141 93 146 53 63 536 26 10
Hepatic infarction 0 9 20 11 0 3 0 0 43 2 1
Haemorrhage 1 5 5 2 0 1 0 1 15 1 0.3
Sepsis 5 31 26 23 17 17 7 15 141 100 3
Bacterial infection 5 26 16 15 7 10 3 8 90 64 2
Viral infection 0 0 2 2 4 3 2 4 17 12 0.3
Fungal infection 0 3 3 3 3 1 0 0 13 9 0.2
Not designated 0 2 5 3 3 3 2 3 21 15 0.4
Rejection 4 42 139 215 200 242 91 117 1050 100 19
Chronic rejection 0 0 0 167 186 229 88 114 784 75 14
Acute rejection 3 38 129 37 10 9 3 3 232 22 4
Not designated 1 4 10 11 4 4 0 0 34 3 1
Recurrence of initial disease 1 9 7 57 73 196 93 190 626 100 11
Non-tumoral 1 9 7 56 70 190 89 185 607 97 11
Tumoral 0 0 0 1 3 6 4 5 19 3 0.3
Tumor de novo 2 3 3 6 2 1 3 2 22 100 0.4
Other liver causes 41 53 89 137 49 87 48 99 603 100 11
Other or unknown causes 15 41 58 56 25 27 9 22 1413 100 25
Total 218 1459 1126 831 486 728 291 457 5596 100 100
Frontiers in Liver Transplantation
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JOURNAL OF HEPATOLOGYpatients, and a large predominance within this group of patients
with alcoholic (20%) and virus C related cirrhosis, (2) the major
change is occurring for cancer, mainly HCC, which represents cur-
rently 20% of all indications, after a signiﬁcant decrease from 50%
in the eighties to only 10% in the nineties. The better selection of
patients within the Milan criteria [20] with consequently equiv-
alent results of survival between HCC and benign hepatic disease
obviously explains this evolution.
One of themost important ﬁndings in the evolution of LT is the
signiﬁcant improvement of results with time, leading presently to
a 1-year survival rate of 85%, all indications confounded. This
results probably from a greater surgical expertise, a better
selection of patients and an improved post-LT management of
complications and immunosuppressive therapy. The improve-
ment is particularly signiﬁcant for cancers, mainly hepatocellular
carcinoma as previously mentioned, with a gain of 36% in 1-year
survival rates from 1990 to 2004. This gain was conﬁrmed with
the data of the last 10 years with an improved 5-year survival of
66%.
Donor and recipient age inﬂuence the quality of the results, as
shown by a previous analysis of ELTR data focused on mortality
after LT [13,14]. However, they are not prominent factors of mor-
tality. Despite the fact that donor age >55 has been demonstrated
as an independent risk factor of post-transplant outcome [13],
the evolution shows that older donors are increasingly used to
augment the donor pool. Similarly, recipient age has been consid-
ered as independently associated with higher post-transplant
mortality, the but older recipients increasingly undergo LT owing
to improved results and better selection of patients.
What has not changed with time is the critical period of the
ﬁrst 6 months and, more generally, the ﬁrst year to determine
the ﬁnal outcome of the transplanted recipients. More than a half
of the deaths and three quarters of re-LTs occurred within the
ﬁrst year after LT. That means that when patients have success-
fully reached the ﬁrst year after LT, they have an optimal chance
to survive at long-term.
When required (in approximately 7% of patients), re-LT is
associated with much less optimal results than the ﬁrst LT. How-
ever, there is no team that would consider this result a reason to
exclude a new LT suggesting that a sort of moral contract exists
with the patient, in addition to strict consideration of the optimal
use of organs. Interestingly, the gap of survival is observed
between ﬁrst and second LT while third and fourth LTs are not
associated with results much worse than those of second LTs.
One of the prominent features of recent years has been the
development of LRLT, performed by almost half of the centers.Journal of Hepatology 201As with split LT, LRLT aims to provide more patients with trans-
plants, but with special attention to decrease as much as possible
risks for the donor, now estimated to be of 0.18% for mortality
and 23% for postoperative morbidity. However, LRLT has tended
to decrease in recent years in Europe mirroring the trend in the
US, where it has actually decreased [21]. Potential living liver
donors are best served by accurate information about donor mor-
tality. Access to such data is difﬁcult and these individuals beneﬁt
from living liver donor registries and peer-reviewed publication
of donor mortality. That may provide an impetus for centers with
unreported deaths to submit these outcomes to the liver trans-
plantation community [22,23].
In conclusion, LT is deﬁnitely a validated therapy of end-stage
liver disease, acute liver failure and HCC. It is becoming relatively
safe as compared to the initial years. Indications are oriented to
more optimal use of the limited donor pool. Survival is increasing
gradually in relation to greater expertise in the surgical proce-
dure and management of immunosuppressive therapy. Alterna-
tives to conventional use of cadaveric full size liver grafts are
expanding to palliate the organ shortage. This latter development
including the increasing use of non-heart beating donors, the
long-term evaluation of the MELD allocation policy now used in
the majority of countries will probably represent a key issue in
the near future. To increase the donor pool, to avoid patient death
on the waiting list, and to offer equal access to good indications of
LT have become the main challenges of a treatment that pres-
ently allows 70–80% of patients to survive at 5 years.Conﬂict of interest
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